Compare ONTF & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONTF | LXEO |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.2M | 369.8M |
| IPO Year | 2021 | 2023 |
| Metric | ONTF | LXEO |
|---|---|---|
| Price | $8.10 | $4.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $8.10 | ★ $18.44 |
| AVG Volume (30 Days) | ★ 986.7K | 731.1K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.67 | ★ 39.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $139,312,000.00 | $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.51 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.70 | $3.60 |
| 52 Week High | $8.11 | $10.99 |
| Indicator | ONTF | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 67.87 | 35.19 |
| Support Level | $7.84 | N/A |
| Resistance Level | N/A | $7.90 |
| Average True Range (ATR) | 0.02 | 0.33 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 88.89 | 2.84 |
ON24 Inc provides a cloud-based intelligent engagement platform that combines experiences with personalization and content, to enable sales and marketing organizations to capture and act on connected insights at scale. The company's platform offers a portfolio of interactive and hyper-personalized digital experience products that create and capture actionable, real-time data at scale from millions of professionals to provide businesses with buying signals and behavioral insights to efficiently convert prospects into customers. It provides solutions to Financial services, Life Sciences, Life sciences, Insurance, Technology, Associations, and Others. Geographically, the company derives maximum revenue from United States, and also has its presence in EMEA and Other Countries.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.